Neurology

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
Monday, April 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, Pharmacology, Conference, Survival, Coya, Associate, Patient, Biomarker, COYA, Medulla oblongata, Death, Society, Doctor of Philosophy, Therapy, Poster, FDA

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.
  • The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.
  • During the Johnson Center Symposium, Dr. Appel will present data correlating 4-HNE levels to bulbar and limb onset ALS.
  • Coya plans to discuss the validation of 4-HNE as a new potential biomarker for ALS and the potential inclusion of 4-HNE as a biomarker in the planned Ph.

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Retrieved on: 
Monday, April 8, 2024
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Wolfram syndrome, Medication, Metabolism, Patient, AMX0035, Samuel, Immunology, Doctor of Philosophy, MD, Trial of the century, Amylyx Pharmaceuticals, Division, Disorder, Pathology, Pharmaceutical industry

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.

Key Points: 
  • A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.
  • Dr. Fumihiko Urano is a physician and medical researcher specializing in Wolfram syndrome.
  • Dr. Urano is a driving force in the study of Wolfram syndrome and related disorders, including WFS1-related disorders/Wolfram-like disorders.
  • As director of the Wolfram Syndrome Clinic and the Wolfram Syndrome International Registry & Clinical Study at Washington University, Dr. Urano treats patients with Wolfram syndrome and related disorders, and leads basic science, clinical, translational, and interventional studies of Wolfram syndrome and related disorders.

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

Retrieved on: 
Monday, April 8, 2024
Fund Raising, Professional Services, Foundation, Philanthropy, Neurology, DEI (Diversity, Equity and Inclusion), Fitness & Nutrition, Biotechnology, Health, Food, Beverage, University, Preschool, Primary, Secondary, Retail, Education, Pharmaceutical, Oncology, Annual report, Organization, Health equity, Building, House, Investment, CSR

Takeda ( TSE:4502/NYSE:TAK ) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program.
  • Combined with previous investments since 2021, Takeda’s total contribution to these initiatives now amounts to $54.1 million.
  • By leveraging this collaborative approach, Takeda provides support to address these critical needs and make a positive impact on people's lives.
  • Further details on the company’s U.S. CSR, health equity and diversity, equity and inclusion programs can be found in the report.

Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Retrieved on: 
Tuesday, April 9, 2024
Knowledge, Neurology, Acadia Pharmaceuticals, Pediatrics, CDKL5, Communication, RTT, Patient, FOXG1, Research, Disorder, Competitive landscape, Rett syndrome, Drug development, USFDA

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Key Points: 
  • HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
    Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
  • The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
  • Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
  • Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.

Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Retrieved on: 
Tuesday, April 9, 2024
Knowledge, Neurology, Acadia Pharmaceuticals, Pediatrics, CDKL5, Communication, RTT, Patient, FOXG1, Research, Disorder, Competitive landscape, Rett syndrome, Drug development, USFDA

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Key Points: 
  • HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
    Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
  • The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
  • Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
  • Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

NeuroCatch Introduces PeakSelect, Enabling a Deeper Clinical Dive into Brain Vital Signs at a Doctor's Office Near You

Retrieved on: 
Tuesday, April 9, 2024
Research, MD–PhD, Blood pressure, Neurology, Brain, Concussion, Mass General Brigham, Vital signs, Clinical, Neuro, Patient, Mental health, Thermoregulation, MD, Athlete, Medicine, Detroit Lions, Dementia, Sport, ERPs, Medical device

BOSTON, April 9, 2024 /PRNewswire/ -- NeuroCatch Inc., a leading medical device company that enables rapid access to an objective assessment of brain health at the point of care, today announced the release of PeakSelect, an innovative software tool designed to improve clinical decision making. An enhancement to the NeuroCatch Platform, PeakSelect allows users to evaluate specific brain vital sign responses for precision medicine in patients undergoing portable neuro-physiological brain function assessment.

Key Points: 
  • An enhancement to the NeuroCatch Platform, PeakSelect allows users to evaluate specific brain vital sign responses for precision medicine in patients undergoing portable neuro-physiological brain function assessment.
  • "The first of an ongoing cadence of planned software upgrades, PeakSelect enhances the impact of NeuroCatch's brain health vital sign data to inform better clinical decision-making, more robust clinical trials, and more effective training regimes."
  • Through regular, over-the-air updates, NeuroCatch is continually advancing the powerful impact of brain vital sign monitoring for frontline health impacts.
  • "The NeuroCatch platform has already proven itself a breakthrough device with its mobile ability, rapid analysis and sophisticated sensitivity to analyze brain vital sign data.

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Retrieved on: 
Tuesday, April 9, 2024
Neurology, Neuroprotection, Element, Conference call, Institutional review board, Cerebrospinal fluid, Survival, Disease, ALS, SPA, Bone marrow, CSF, Data monitoring committee, Webcast, Patient, Protocol, Biomarker, Mortality, Microsoft Exchange Server, Stem cell, DMC, Screening, Agency, Safety, CAFS, Brainstorm, Therapy, Marketing, FDA, BLA, Neuroinflammation, Food, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). 

Key Points: 
  • (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
  • The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.
  • We appreciate the Agency's engagement and guidance during the SPA process and look forward to moving forward with the study."
  • The Phase 3b trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS.

Schwarzman Animal Medical Center Releases 2023 Numbers, Recapping a Year of Comprehensive Care

Retrieved on: 
Monday, April 8, 2024
Animal Medical Center, Denise, RN, Conference, Neurology, Human, Partnership, Patient, Working dog, Zoo, Trauma, Female, Intensive care unit, Blog, Wildlife Conservation Society, Veterinary medicine, Local, Veterinarian, MBA, Morale, Male, Dog, Wildlife, Euthanasia, AMC, Lemur, Bronx Zoo, Cat, Pet, Family, Animal, Total, Nursing

NEW YORK, April 8, 2024 /PRNewswire/ -- As the world's largest veterinary teaching hospital dedicated to the advancement of veterinary medicine, Schwarzman Animal Medical Center (AMC) announces its official 2023 numbers – recapping a year of comprehensive and compassionate care as New York City's only level 1 trauma center.

Key Points: 
  • "As New York City's only level 1 veterinary trauma center, we're honored to provide world-class, compassionate care to animals for over 110 years.
  • Dr. Ann Hohenhaus, Senior Veterinarian in Oncology and the Director of Pet Health Information at Animal Medical Center, elaborated on the impact of charitable giving.
  • Later in 2024, the Animal Medical Center will see the opening of the newly expanded Emergency Room, Intensive Care Unit and Medical Surgical Unit, with expected project completion in 2025.
  • With a team of 130+ veterinarians across more than 20 specialties, the Animal Medical Center provides world-class medical care to dogs, cats, and exotic pets and is open 365 days a year and operates 24/7.

Praxis Precision Medicines to Host PRAX-628 Program Update

Retrieved on: 
Monday, March 25, 2024
Praxis, Neurology, Epilepsy, NYU, Central nervous system, CNS

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m. ET. To register, click here.

Key Points: 
  • Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m.
  • ET
    Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine
    BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m.
  • ET.
  • To register, click here .